VTCN1 and breast cancer: A bispecific B7-H4/CD3 antibody has been found to successfully crosslink TCs with B7-H4 with human CD4 and CD8 T cell receptors, inducing T cells to lyse B7-H4+ breast cancer cells both in vivo and in vitro [119].